As of 2024-09-14, the EV/EBITDA ratio of Nektar Therapeutics (NKTR) is -1.58. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NKTR's latest enterprise value is 213.20 mil USD. NKTR's TTM EBITDA according to its financial statements is -135.10 mil USD. Dividing these 2 quantities gives us the above NKTR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.6x - 13.4x | 13.1x |
| Forward P/E multiples | 17.5x - 21.4x | 20.4x |
| Fair Price | (12.71) - (9.68) | (12.16) |
| Upside | -1069.9% - -839.1% | -1028.2% |
| Date | EV/EBITDA |
| 2024-09-13 | -1.58 |
| 2024-09-12 | -1.50 |
| 2024-09-11 | -1.50 |
| 2024-09-10 | -1.48 |
| 2024-09-09 | -1.40 |
| 2024-09-06 | -1.32 |
| 2024-09-05 | -1.33 |
| 2024-09-04 | -1.48 |
| 2024-09-03 | -1.48 |
| 2024-08-30 | -1.54 |
| 2024-08-29 | -1.52 |
| 2024-08-28 | -1.51 |
| 2024-08-27 | -1.50 |
| 2024-08-26 | -1.65 |
| 2024-08-23 | -1.63 |
| 2024-08-22 | -1.44 |
| 2024-08-21 | -1.52 |
| 2024-08-20 | -1.54 |
| 2024-08-19 | -1.61 |
| 2024-08-16 | -1.50 |
| 2024-08-15 | -1.41 |
| 2024-08-14 | -1.35 |
| 2024-08-13 | -1.36 |
| 2024-08-12 | -1.31 |
| 2024-08-09 | -1.31 |
| 2024-08-08 | -1.44 |
| 2024-08-07 | -1.40 |
| 2024-08-06 | -1.39 |
| 2024-08-05 | -1.39 |
| 2024-08-02 | -1.43 |
| 2024-08-01 | -1.52 |
| 2024-07-31 | -1.62 |
| 2024-07-30 | -1.69 |
| 2024-07-29 | -1.65 |
| 2024-07-26 | -1.67 |
| 2024-07-25 | -1.66 |
| 2024-07-24 | -1.71 |
| 2024-07-23 | -1.81 |
| 2024-07-22 | -1.78 |
| 2024-07-19 | -1.69 |
| 2024-07-18 | -1.63 |
| 2024-07-17 | -1.77 |
| 2024-07-16 | -1.80 |
| 2024-07-15 | -1.70 |
| 2024-07-12 | -1.73 |
| 2024-07-11 | -1.65 |
| 2024-07-10 | -1.61 |
| 2024-07-09 | -1.47 |
| 2024-07-08 | -1.48 |
| 2024-07-05 | -1.55 |